Identification of a Risk Profile Associated with Failure of the Hybrid Ablation of Atrial Fibrillation.

Identification of a Risk Profile Associated with Failure of the Hybrid Ablation of Atrial Fibrillation. - Hybrid AF Ablation

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON47743

Enrollment

250

Registered

2015-01-20

Start date

2015-02-09

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atrial fibrillation

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Potential candidates for the study have agreed to undergo the hybrid AF ablation procedure.

Exclusion criteria

Exclusion criteria: There are no specific exclusion criteria.

Design outcomes

Primary

Measure	Time frame
Primary outcome is failure of the hybrid AF ablation, i.e. any (a)symptomatic AF/AFL/AT >30 sec without anti-arrhythmic drugs determined at 1 year of follow-up by ECG recording and prolonged Holter monitoring.	—

Secondary

Measure	Time frame
Secondary outcomes concern the identification of a risk profile associated with (long-term) failure or succes of the procedure, the number of patients requiring endocardial ablation in addition to epicardial ablation during the procedure, the electrophysiological findings (voltage, areas of fractionated potentials) during the procedure, the incidence and type of supraventricular tachyarrhythmias following the procedure, the changes in left atrial size and function, the use of anti-arrhythmic drugs, the frequency of repeated ablations, the quality of life and physical activity, and the adipose tissue biomarkers that are associated with the progression, prognosis and other markers of atrial fibrillation.	—

Measure

Time frame

Secondary outcomes concern the identification of a risk profile associated with (long-term) failure or succes of the procedure, the number of patients requiring endocardial ablation in addition to epicardial ablation during the procedure, the electrophysiological findings (voltage, areas of fractionated potentials) during the procedure, the incidence and type of supraventricular tachyarrhythmias following the procedure, the changes in left atrial size and function, the use of anti-arrhythmic drugs, the frequency of repeated ablations, the quality of life and physical activity, and the adipose tissue biomarkers that are associated with the progression, prognosis and other markers of atrial fibrillation.

—

Countries

Netherlands

Outcome results